CSPC Pharmaceutical's meloxicam injection (III) receives approval in China

CSPC Pharmaceutical Group Limited (HKEX:1093) announced that its Meloxicam Injection (III) has received drug registration approval from China's National Medical Products Administration. This approval positions the product as a first-of-its-kind intravenously administered nanocrystal formulation for treating moderate to severe pain in adults. Utilizing novel nanotechnology, the drug reduces particle size to the nanometer range, enabling high-dose, rapid intravenous administration for the treatment of acute moderate to severe postoperative pain. Management believes this formulation offers rapid onset, strong analgesic effect, and long-lasting action, with a good safety profile. The company expects Meloxicam Injection (III) to become a superior treatment option for the management of acute moderate to severe pain. The approval enriches CSPC Pharmaceutical's therapeutic portfolio and reinforces its position in nanomedicine research and development.